Joanne Zhung, MD
Radiation Oncology · Nyack, NYNPI 1619296092
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,750 of the $2,654 with a category attached, or 65.9%. Novocure Inc. accounts for 81.7% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $2,047 and has fallen 87.5% since, to $256 in 2025.
Across 35 payments — averaging $75.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$2K
- AstraZeneca$292
- Amgen$52
- Medtronic$41
- Merck$29
- Genentech USA, Inc.$16
- plus $54 from 4 others
What the payments were for
- Speaking & faculty fees$1,75066%
- Travel & lodging$2218%
- Food & beverage$68326%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 8 | $2,170 |
| AstraZeneca | 16 | $292 |
| Amgen | 3 | $52 |
| Medtronic | 1 | $41 |
| Merck | 2 | $29 |
| Genentech USA, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Eisai Inc. | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $11 |
How this compares
$2,654 in reported general payments places this provider in the 80th percentile of 397 radiation oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Silver Sulfadiazine | 17 | $192 |
| Dexamethasone | 15 | $166 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Nyack
- Miriam KnollNyack$29K
- Chung ChungSyracuse$3.1M
- Michael ZelefskyNew York$946K
- Jeffrey BogartSyracuse$772K
- Steven FinkelsteinSyracuse$578K
- Shawn ZimbergPlainview$411K
- Edward ObedianOyster Bay$391K
- Nancy LeeNew York$233K
- Dheerendra PrasadBuffalo$178K
- Robert SamsteinNew York$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.